Isradipine augmentation of virtual reality cue exposure therapy for tobacco craving: a triple-blind randomized controlled trial.

Autor: Young CC; School of Nursing, The University of Texas at Austin, Austin, TX, USA. cyoung@mail.nur.utexas.edu., Papini S; Department of Psychology, University of Hawai'i at Mānoa, Honolulu, HI, USA., Minami H; Department of Psychology, Fordham University, New York, NY, USA., Morikawa H; Department of Neuroscience and Waggoner Center for Alcohol and Addiction Research, The University of Texas at Austin, Austin, TX, USA., Otto MW; Department of Psychological and Brain Sciences, Boston University, Boston, MA, USA., Roache JD; Division of Alcohol & Drug Addiction, Department of Psychiatry & Behavioral Sciences, University of Texas Health Science Center, San Antonio, TX, USA., Smits JAJ; Department of Psychology and Institute for Mental Health Research, The University of Texas at Austin, Austin, TX, USA.
Jazyk: angličtina
Zdroj: Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology [Neuropsychopharmacology] 2024 Oct; Vol. 49 (11), pp. 1711-1718. Date of Electronic Publication: 2024 May 24.
DOI: 10.1038/s41386-024-01872-9
Abstrakt: Preclinical research with rodents suggests that the L-type calcium channel blocker isradipine can enhance long-term extinction of conditioned place preference for addictive substances when it is administered in conjunction with extinction training. Although isradipine alone, which is FDA-approved for hypertension, has not shown a direct effect on craving in human drug users, its potential to augment behavioral treatments designed to reduce craving remains unknown. We conducted a triple-blind, randomized placebo-controlled pilot clinical trial of isradipine combined with a novel virtual reality cue exposure therapy (VR-CET) approach with multimodal cues that targeted craving. After 24 hours of abstinence, 78 adults with an ongoing history of daily cigarette use received isradipine (n = 40) or placebo (n = 38) and reported craving levels after each of 10 trials of VR-CET. Consistent with pre-registered hypotheses, the isradipine group had significantly lower mean craving across cue exposure trials at the medication-free 24-hour follow-up (d = -0.42, p = 0.046). There were no serious adverse events; however, side effects such as headache and dizziness occurred more frequently in the isradipine group. The findings of the current study support follow-up clinical trials that specifically test the efficacy of isradipine-augmented VR-CET for reducing smoking relapse rates after an initial quit attempt. clinicaltrials.gov: NCT03083353.
(© 2024. The Author(s), under exclusive licence to American College of Neuropsychopharmacology.)
Databáze: MEDLINE
Externí odkaz: